In the 2022 ELN guidelines, all adult KMT2A-r AML except for KMT2A::MLLT3 were regarded as high risk with very adverse outcomes.4 However, this did not seem to work well in pediatric AML. The gene discussed is MLLT3; the disease is acute myeloid leukemia.